The global HIV drugs market size reached US$ 30.5 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 38.8 Billion by 2028, exhibiting a growth rate (CAGR) of 3.95% during 2023-2028.
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. The report has categorized the market based on drug class and distribution channel.Breakup by Drug Class:
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global HIV drugs market report, along with forecasts at the global and regional levels from 2023-2028. The report has categorized the market based on drug class and distribution channel.Breakup by Drug Class:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report
1. What was the size of the global HIV drugs market in 2022?2. What is the expected growth rate of the global HIV drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
Table of Contents
1 Preface3 Executive Summary
2 Scope and Methodology
4 Introduction
5 Global HIV Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 HIV Drugs Manufacturing Process
10 Competitive Landscape
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Merck & Co. Inc.
- ViiV Healthcare
- AbbVie
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Gilead Sciences Inc.
- Johnson & Johnson
- Cipla Limited
- Daiichi Sankyo
- Emcure
- Hetero Drugs
- Mylan
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | September 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 30.5 Billion |
| Forecasted Market Value ( USD | $ 38.8 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
